

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

S/21/03  
RP

# Request For Continued Examination (RCE) Transmittal

Address to:  
Commissioner for Patents  
Box RCE  
Washington, DC 20231

<b>Application Number</b>	09/985,974
<b>Filing Date</b>	November 7, 2001
<b>First Named Inventor</b>	Jorge D. Brioni
<b>Art Unit</b>	1617
<b>Examiner Name</b>	Bahar, Mojdeh
<b>Attorney Docket Number</b>	6753.US.02

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application.

Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

## 1. Submission required under 37 CFR 1.114

- a.  Previously submitted
  - i.  Consider the amendment(s)/reply under 37 CFR 1.116 previously filed on \_\_\_\_\_  
(Any unentered amendment(s) referred to above will be entered).
  - ii.  Consider the arguments in the Appeal Brief or Rely Brief previously filed on \_\_\_\_\_
  - iii.  Other \_\_\_\_\_
- b.  Enclosed
  - i.  Amendment/Reply
  - ii.  Affidavit(s)/Declaration(s)
  - iii.  Information Disclosure Statement (IDS)
  - iv.  Other Petition to Revive

RECEIVED  
MAR 26 2003

OFFICE OF PETITIONS

## 2. Miscellaneous

- a.  Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of three months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)
- b.  Other \_\_\_\_\_

## 3. Fees

- The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.  
The Director is hereby authorized to charge the following fees, or credit any overpayments, to
- a.  Deposit Account No. 01-0025 03/25/2003 DHGUYEM1 00000102 010025 09985974
  - i.  RCE fee required under 37 CFR 1.17(e) 02 FC:1801 750.00 CH
  - ii.  Extension of time fee (37 CFR 1.136 and 1.17) 03 FC:1253 930.00 CH
  - iii.  Other Petition to Revive of an Application for Patent Abandoned Unintentionally
  - b.  Check in the amount of \$ \_\_\_\_\_ enclosed
  - c.  Payment by credit card (Form PTO-2038 enclosed)

**WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

Name (Print/Type)	Michael J. Ward	Registration No. (Attorney/Agent)	09985974
Signature		Date	3/18/03

## CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner For Patents, Box RCE, Washington, DC 20231, or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.

Name (Print/Type)	Tanya M. Parent	Date	March 18, 2003
Signature		Page	1 of 2

This collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public which is to be provided by the USPTO to process an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Box RCE, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option

Adjustment  
03/25/2003  
03 FC:1801  
03 FT:1253



PATENTS

#12

5/21/03  
MP

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Brioni, et al.

Group Art No.: 1617

Serial No.: 09/985,974

Examiner: Bahar, Mojdeh

Filed: November 7, 2001

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:  
Box RCE  
Commissioner for Patents  
Washington, D.C. 20231, on:

Title: THE USE OF SELECTIVE  
DOPAMINE BY RECEPTOR AGONISTS  
FOR TREATING SEXUAL  
DYSFUNCTION

Date of Deposit: March 18, 2003

Case No.: 6753.US.02

Tanya Parent Date

Box RCE  
Commissioner for Patents  
Washington, D.C. 20231

RECEIVED

MAR 26 2003

RESPONSE

OFFICE OF PETITIONS

Dear Sir:

This communication is responsive to the Office Action dated September 10, 2002 and is accompanied by a Petition To Revive An Unintentionally Abandoned Application under 37 C.F.R. §1.137 (b)(3).

Claims 1-30 are pending.

Claims 1, 5, 15-22, 26, 2, 4, 6, 8, 9, 11, 12, 14, 23, 25, 27 and 29 stand rejected.

Applicants reserve the right to file divisional applications on all non-elected subject matter of the instant application.

The Applicants mistakenly elected claims 16 and 39 in the August 8, 2002 Response, where claims 14 and 29 should have been elected.

Claims 1, 5, 22 and 26 (all in part), 2, 4, 6, 8, 9, 11, 12, 14, 23, 25, 27 and 29 stand rejected under 35 USC 103(a) as unpatentable over Glase et al. and Zorn et al in view of US 5,714,487 to Sanner. Applicants respectfully submit that the cited references do not teach or suggest the use of D4 agonist for treating sexual dysfunction.


Accordingly, Applicants respectfully request allowance of the claims.



23492

ABBOTT LABORATORIES  
Telephone: (847) 938-3490  
Facsimile: (847) 938-2623

Respectfully submitted,  
Brioni, et al.

  
Michael J. Ward  
Registration No. 37,960  
Attorney for Applicants